Filing Details
- Accession Number:
- 0001104659-20-021861
- Form Type:
- 13G Filing
- Publication Date:
- 2020-02-14 16:26:35
- Filed By:
- Quaker Bioventures Ii Lp
- Company:
- Tela Bio Inc.
- Filing Date:
- 2020-02-14
- SEC Url:
- 13G Filing
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
Quaker BioVentures II | 0 | 1,769,196 | 0 | 1,769,196 | 1,769,196 | 15.5% |
Quaker BioVentures Capital II | 0 | 1,769,196 | 0 | 1,769,196 | 1,769,196 | 15.5% |
Quaker BioVentures Capital II | 0 | 1,769,196 | 0 | 1,769,196 | 1,769,196 | 15.5% |
| SECURITIES AND EXCHANGE COMMISSION |
|
| Washington, D.C. 20549 |
|
|
|
|
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. N/A)*
TELA Bio, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
872381108
(CUSIP Number)
Brian Schwenk
Quaker BioVentures II, L.P.
150 Monument Road, Suite 207
Bala Cynwyd, Pennsylvania 19004
(215) 988-6800
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
December 31, 2019
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
o | Rule 13d-1(b) |
x | Rule 13d-1(c) |
o | Rule 13d-1(d) |
*The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 872381108 | SCHEDULE 13G |
| |||||
| |||||||
| 1 | Name of Reporting Person Quaker BioVentures II, L.P. | |||||
| |||||||
| 2 | Check the Appropriate Box if a Member of a Group | |||||
|
| (a) | o | ||||
|
| (b) | o | ||||
| |||||||
| 3 | SEC Use Only | |||||
| |||||||
| 4 | Citizenship or Place of Organization | |||||
|
|
| |||||
Number of | 5 | Sole Voting Power | |||||
| |||||||
6 | Shared Voting Power * | ||||||
| |||||||
7 | Sole Dispositive Power | ||||||
| |||||||
8 | Shared Dispositive Power * | ||||||
| |||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person | |||||
| |||||||
| 10 | Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares o | |||||
| |||||||
| 11 | Percent of Class Represented by Amount in Row (9)** | |||||
| |||||||
| 12 | Type of Reporting Person | |||||
* Includes (i) 1,769,196 shares of common stock, par value $0.001 per share (the Shares), of TELA Bio, Inc. (the Issuer) and (ii) 18,096 Shares issuable upon the exercise of warrants to purchase Shares (the Warrants).
** This percentage is calculated based upon 11,405,543 Shares outstanding, as set forth in the Issuers Quarterly Report on Form 10-Q with the Securities and Exchange Commission (SEC) on December 18, 2019, and includes an additional 18,096 Shares subject to currently exercisable Warrants held by the Reporting Persons.
2
CUSIP No. 872381108 |
|
| |||||
| |||||||
| 1 | Name of Reporting Person Quaker BioVentures Capital II, L.P | |||||
| |||||||
| 2 | Check the Appropriate Box if a Member of a Group | |||||
|
| (a) | o | ||||
|
| (b) | o | ||||
| |||||||
| 3 | SEC Use Only | |||||
| |||||||
| 4 | Citizenship or Place of Organization | |||||
|
|
| |||||
Number of | 5 | Sole Voting Power | |||||
| |||||||
6 | Shared Voting Power * | ||||||
| |||||||
7 | Sole Dispositive Power | ||||||
| |||||||
8 | Shared Dispositive Power * | ||||||
| |||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person | |||||
| |||||||
| 10 | Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares o | |||||
| |||||||
| 11 | Percent of Class Represented by Amount in Row (9)** | |||||
| |||||||
| 12 | Type of Reporting Person | |||||
* Includes (i) 1,769,196 Shares, of the Issuer and (ii) 18,096 Shares issuable upon the exercise of Warrants.
** This percentage is calculated based upon 11,405,543 Shares outstanding, as set forth in the Issuers Quarterly Report on Form 10-Q with the SEC on December 18, 2019, and includes an additional 18,096 Shares subject to currently exercisable Warrants held by the Reporting Persons.
3
CUSIP No. 872381108 |
|
| |||||
| |||||||
| 1 | Name of Reporting Person Quaker BioVentures Capital II, LLC | |||||
| |||||||
| 2 | Check the Appropriate Box if a Member of a Group | |||||
|
| (a) | o | ||||
|
| (b) | o | ||||
| |||||||
| 3 | SEC Use Only | |||||
| |||||||
| 4 | Citizenship or Place of Organization | |||||
|
|
| |||||
Number of | 5 | Sole Voting Power | |||||
| |||||||
6 | Shared Voting Power * | ||||||
| |||||||
7 | Sole Dispositive Power | ||||||
| |||||||
8 | Shared Dispositive Power * | ||||||
| |||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person | |||||
| |||||||
| 10 | Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares o | |||||
| |||||||
| 11 | Percent of Class Represented by Amount in Row (9)** | |||||
| |||||||
| 12 | Type of Reporting Person | |||||
* Includes (i) 1,769,196 Shares, of the Issuer and (ii) 18,096 Shares issuable upon the exercise of Warrants.
** This percentage is calculated based upon 11,405,543 Shares outstanding, as set forth in the Issuers Quarterly Report on Form 10-Q with the SEC on December 18, 2019, and includes an additional 18,096 Shares subject to currently exercisable Warrants held by the Reporting Persons.
4
ORIGINAL REPORT ON SCHEDULE 13G
Item 1. | ||
| (a) | Name of Issuer: |
| (b) | Address of Issuers Principal Executive Offices: |
| ||
Item 2. | ||
| (a) | Name of Person Filing: Quaker BioVentures Capital II, L.P. Quaker BioVentures Capital II, LLC. |
| (b) | Address of Principal Business Office: |
| (c) | Citizenship: Quaker BioVentures Capital II, L.P. - Delaware Quaker BioVentures Capital II, LLC - Delaware |
| (d) | Title and Class of Securities: |
| (e) | CUSIP Number: |
| ||
Item 3. | Not applicable. |
5
Item 4. | Ownership. | ||
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. | |||
| (a) | Amount beneficially owned. Quaker BioVentures II, L.P. - 1,769,196 Quaker BioVentures Capital II, L.P. - 1,769,196 Quaker BioVentures Capital II, LLC - 1,769,196 | |
| (b) | Percent of class. Quaker BioVentures II, L.P. 15.5% Quaker BioVentures Capital II, L.P. 15.5% Quaker BioVentures Capital II, LLC 15.5% | |
| (c) | Number of shares as to which such person has:
| |
|
| (i) | Sole power to vote or to direct the vote: Quaker BioVentures II, L.P. 0 Quaker BioVentures Capital II, L.P. 0 Quaker BioVentures Capital II, LLC 0 |
|
| (ii) | Shared power to vote or to direct the vote: Quaker BioVentures II, L.P. - 1,769,196 Quaker BioVentures Capital II, L.P. - 1,769,196 Quaker BioVentures Capital II, LLC - 1,769,196 |
|
| (iii) | Sole power to dispose or to direct the disposition of: Quaker BioVentures II, L.P. 0 Quaker BioVentures Capital II, L.P. 0 Quaker BioVentures Capital II, LLC 0 |
|
| (iv) | Shared power to dispose or to direct the disposition of: Quaker BioVentures II, L.P. - 1,769,196 Quaker BioVentures Capital II, L.P. - 1,769,196 Quaker BioVentures Capital II, LLC - 1,769,196 |
| |||
All beneficial ownership amounts disclosed above include 18,096 Shares issuable upon the exercise of Warrants. Quaker BioVentures Capital II, L.P. is the general partner of Quaker BioVentures II, L.P., and Quaker BioVentures Capital II, LLC is the general partner of Quaker Capital L.P. | |||
| |||
Item 5. | Ownership of Five Percent or Less of a Class | ||
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o. | |||
| |||
Item 6. | Ownership of More than Five Percent on Behalf of Another Person | ||
Not applicable. | |||
| |||
Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company | ||
Not applicable. | |||
| |||
Item 8. | Identification and Classification of Members of the Group | ||
Each of the Reporting Persons may be deemed to be a member of a group with respect to the issuer or securities of the issuer for the purpose of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended. | |||
| |||
Item 9. | Notice of Dissolution of Group | ||
Not applicable. |
6
Item 10. | Certification |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having the purpose or effect. |
Signatures
After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.
Date: February 14, 2020
| QUAKER BIOVENTURES II, L.P. | ||
|
| ||
| By: Quaker BioVentures Capital II, L.P., its general partner | ||
|
| ||
| By: Quaker BioVentures Capital II, LLC, its general partner | ||
|
| ||
| /s/ Adele C. Oliva | ||
| Name: | Adele C. Oliva | |
| Title: | Executive Manager | |
|
| ||
| QUAKER BIOVENTURES CAPITAL II, L.P. | ||
|
| ||
| By: Quaker BioVentures Capital II, LLC, its general partner | ||
|
| ||
| /s/ Adele C. Oliva | ||
| Name: | Adele C. Oliva | |
| Title: | Executive Manager | |
|
| ||
| QUAKER BIOVENTURES CAPITAL II, LLC | ||
|
| ||
| /s/ Adele C. Oliva | ||
| Name: | Adele C. Oliva | |
| Title: | Executive Manager | |
7